Effects of Pentoxifylline on Serum Markers of Diabetic Nephropathy in Type 2 Diabetes View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-04-05

AUTHORS

Fatemeh Moosaie, Soghra Rabizadeh, Aida Fallahzadeh, Ali Sheikhy, Alipasha Meysamie, Fatemeh Dehghani Firouzabadi, Manouchehr Nakhjavani, Alireza Esteghamati

ABSTRACT

ObjectiveTo investigate the effects of pentoxifylline (PTX) in combination with losartan compared to the high dose of losartan alone on serum markers of diabetic nephropathy such as HSP70, copeptin, CRP, and TNFα in patients with type 2 diabetes and nephropathy.MethodsA single-center, randomized, double-blind, open-label clinical trial was conducted. Sixty-two patients were eligible and allocated to “PTX + losartan” and “high-dose losartan” arms of the trial using software for random number generation. The first arm received 400 mg PTX two times a day (BD) plus 50 mg losartan daily, while the second arm received 50 mg losartan two times a day (BD) for 12 weeks. Comparison of the biomarkers’ levels before and after treatment was done using paired sample t test variance. ANCOVA was applied to evaluate the comparative efficacy of the two interventions. The effect size was calculated and reported for each biomarker.ResultsUrine albumin excretion (UAE), hs-CRP, and HbA1c significantly decreased in both trial arms compared to the baseline measures. Copeptin and TNFα showed significant differences (after vs before) only in the losartan group (p = 0.017 and p = 0.043, respectively). The losartan arm was more successful in reducing TNFα, copeptin, HSP70, systolic blood pressure (SBP), and diastolic blood pressure (DBP) values (p = 0.045, effect size = 7.3%; p = 0.018, effect size 10.1%; p = 0.046, effect size 4.7%, p = 0.001, effect size 23%; p = 0.012, effect size 10.2%, respectively) and the PTX arm was associated with a superior reduction of UAE and hs-CRP levels (p = 0.018, effect size 9.1%; p = 0.028, effect size 9.2%, respectively).ConclusionAdd-on PTX to losartan may have more effective anti-inflammatory and anti-albuminuric roles and therefore may be more applicable in the management of diabetic nephropathy compared with high-dose losartan alone.Trail RegistrationTrial number IRCT 20121104011356N10. More... »

PAGES

1023-1036

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-022-01250-y

DOI

http://dx.doi.org/10.1007/s13300-022-01250-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1146889445

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35380410


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411705.6", 
          "name": [
            "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moosaie", 
        "givenName": "Fatemeh", 
        "id": "sg:person.010117632767.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010117632767.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411705.6", 
          "name": [
            "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rabizadeh", 
        "givenName": "Soghra", 
        "id": "sg:person.01222717544.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222717544.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411705.6", 
          "name": [
            "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fallahzadeh", 
        "givenName": "Aida", 
        "id": "sg:person.015235114321.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015235114321.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411705.6", 
          "name": [
            "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sheikhy", 
        "givenName": "Ali", 
        "id": "sg:person.013767066337.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013767066337.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Community Medicine, Tehran University of Medical Sciences, Tehran, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411705.6", 
          "name": [
            "Department of Community Medicine, Tehran University of Medical Sciences, Tehran, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meysamie", 
        "givenName": "Alipasha", 
        "id": "sg:person.0774664154.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774664154.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411705.6", 
          "name": [
            "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dehghani Firouzabadi", 
        "givenName": "Fatemeh", 
        "id": "sg:person.013442560033.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013442560033.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411705.6", 
          "name": [
            "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakhjavani", 
        "givenName": "Manouchehr", 
        "id": "sg:person.01244110102.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244110102.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411705.6", 
          "name": [
            "Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Esteghamati", 
        "givenName": "Alireza", 
        "id": "sg:person.01261073742.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261073742.61"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11255-015-0968-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025936794", 
          "https://doi.org/10.1007/s11255-015-0968-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12192-010-0204-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011103613", 
          "https://doi.org/10.1007/s12192-010-0204-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ijo.2008.229", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007469898", 
          "https://doi.org/10.1038/ijo.2008.229"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12933-018-0753-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105978128", 
          "https://doi.org/10.1186/s12933-018-0753-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-198734010-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002334899", 
          "https://doi.org/10.2165/00003495-198734010-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12192-013-0435-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031112118", 
          "https://doi.org/10.1007/s12192-013-0435-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1379/csc-270.1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027491492", 
          "https://doi.org/10.1379/csc-270.1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13098-015-0060-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047012278", 
          "https://doi.org/10.1186/s13098-015-0060-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep17150", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012845912", 
          "https://doi.org/10.1038/srep17150"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-04-05", 
    "datePublishedReg": "2022-04-05", 
    "description": "ObjectiveTo investigate the effects of pentoxifylline (PTX) in combination with losartan compared to the high dose of losartan alone on serum markers of diabetic nephropathy such as HSP70, copeptin, CRP, and TNF\u03b1 in patients with type\u00a02 diabetes and nephropathy.MethodsA single-center, randomized, double-blind, open-label clinical trial was conducted. Sixty-two patients were eligible and allocated to \u201cPTX\u2009+\u2009losartan\u201d and \u201chigh-dose losartan\u201d arms of the trial using software for random number generation. The first arm received 400\u00a0mg PTX two times a day (BD) plus 50\u00a0mg losartan daily, while the second arm received 50\u00a0mg losartan two times a day (BD) for 12\u00a0weeks. Comparison of the biomarkers\u2019 levels before and after treatment was done using paired sample t\u00a0test variance. ANCOVA was applied to evaluate the comparative efficacy of the two interventions. The effect size was calculated and reported for each biomarker.ResultsUrine albumin excretion (UAE), hs-CRP, and HbA1c significantly decreased in both trial arms compared to the baseline measures. Copeptin and TNF\u03b1 showed significant differences (after vs before) only in the losartan group (p\u2009=\u20090.017 and p\u2009=\u20090.043, respectively). The losartan arm was more successful in reducing TNF\u03b1, copeptin, HSP70, systolic blood pressure (SBP), and diastolic blood pressure (DBP) values (p\u2009=\u20090.045, effect size\u2009=\u20097.3%; p\u2009=\u20090.018, effect size 10.1%; p\u2009=\u20090.046, effect size 4.7%, p\u2009=\u20090.001, effect size 23%; p\u2009=\u20090.012, effect size 10.2%, respectively) and the PTX arm was associated with a superior reduction of UAE and hs-CRP levels (p\u2009=\u20090.018, effect size 9.1%; p\u2009=\u20090.028, effect size 9.2%, respectively).ConclusionAdd-on PTX to losartan may have more effective anti-inflammatory and anti-albuminuric roles and therefore may be more applicable in the management of diabetic nephropathy compared with high-dose losartan alone.Trail RegistrationTrial number IRCT 20121104011356N10.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-022-01250-y", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "systolic blood pressure", 
      "effect of pentoxifylline", 
      "diabetic nephropathy", 
      "serum markers", 
      "open-label clinical trial", 
      "diastolic blood pressure values", 
      "high-dose losartan", 
      "hs-CRP levels", 
      "blood pressure values", 
      "losartan group", 
      "losartan arm", 
      "albumin excretion", 
      "hs-CRP", 
      "blood pressure", 
      "trial arms", 
      "clinical trials", 
      "losartan", 
      "high dose", 
      "comparative efficacy", 
      "nephropathy", 
      "type 2", 
      "pentoxifylline", 
      "copeptin", 
      "TNF\u03b1", 
      "baseline measures", 
      "first arm", 
      "two times", 
      "superior reduction", 
      "significant differences", 
      "patients", 
      "second arm", 
      "effect size", 
      "trials", 
      "biomarkers", 
      "sample t", 
      "pressure values", 
      "arm", 
      "markers", 
      "days", 
      "HbA1c", 
      "diabetes", 
      "HSP70", 
      "ObjectiveTo", 
      "CRP", 
      "MethodsA", 
      "excretion", 
      "dose", 
      "weeks", 
      "efficacy", 
      "intervention", 
      "levels", 
      "treatment", 
      "ANCOVA", 
      "effect", 
      "group", 
      "test variance", 
      "management", 
      "differences", 
      "role", 
      "measures", 
      "time", 
      "reduction", 
      "pressure", 
      "combination", 
      "types", 
      "comparison", 
      "variance", 
      "values", 
      "UAE", 
      "size", 
      "generation", 
      "software", 
      "random number generation", 
      "number generation"
    ], 
    "name": "Effects of Pentoxifylline on Serum Markers of Diabetic Nephropathy in Type 2 Diabetes", 
    "pagination": "1023-1036", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1146889445"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-022-01250-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35380410"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-022-01250-y", 
      "https://app.dimensions.ai/details/publication/pub.1146889445"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_927.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-022-01250-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01250-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01250-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01250-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01250-y'


 

This table displays all metadata directly associated to this object as RDF triples.

222 TRIPLES      21 PREDICATES      108 URIs      91 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-022-01250-y schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N1368c938ed8740bab362d487950468f2
4 schema:citation sg:pub.10.1007/s11255-015-0968-2
5 sg:pub.10.1007/s12192-010-0204-z
6 sg:pub.10.1007/s12192-013-0435-x
7 sg:pub.10.1038/ijo.2008.229
8 sg:pub.10.1038/srep17150
9 sg:pub.10.1186/s12933-018-0753-5
10 sg:pub.10.1186/s13098-015-0060-1
11 sg:pub.10.1379/csc-270.1
12 sg:pub.10.2165/00003495-198734010-00003
13 schema:datePublished 2022-04-05
14 schema:datePublishedReg 2022-04-05
15 schema:description ObjectiveTo investigate the effects of pentoxifylline (PTX) in combination with losartan compared to the high dose of losartan alone on serum markers of diabetic nephropathy such as HSP70, copeptin, CRP, and TNFα in patients with type 2 diabetes and nephropathy.MethodsA single-center, randomized, double-blind, open-label clinical trial was conducted. Sixty-two patients were eligible and allocated to “PTX + losartan” and “high-dose losartan” arms of the trial using software for random number generation. The first arm received 400 mg PTX two times a day (BD) plus 50 mg losartan daily, while the second arm received 50 mg losartan two times a day (BD) for 12 weeks. Comparison of the biomarkers’ levels before and after treatment was done using paired sample t test variance. ANCOVA was applied to evaluate the comparative efficacy of the two interventions. The effect size was calculated and reported for each biomarker.ResultsUrine albumin excretion (UAE), hs-CRP, and HbA1c significantly decreased in both trial arms compared to the baseline measures. Copeptin and TNFα showed significant differences (after vs before) only in the losartan group (p = 0.017 and p = 0.043, respectively). The losartan arm was more successful in reducing TNFα, copeptin, HSP70, systolic blood pressure (SBP), and diastolic blood pressure (DBP) values (p = 0.045, effect size = 7.3%; p = 0.018, effect size 10.1%; p = 0.046, effect size 4.7%, p = 0.001, effect size 23%; p = 0.012, effect size 10.2%, respectively) and the PTX arm was associated with a superior reduction of UAE and hs-CRP levels (p = 0.018, effect size 9.1%; p = 0.028, effect size 9.2%, respectively).ConclusionAdd-on PTX to losartan may have more effective anti-inflammatory and anti-albuminuric roles and therefore may be more applicable in the management of diabetic nephropathy compared with high-dose losartan alone.Trail RegistrationTrial number IRCT 20121104011356N10.
16 schema:genre article
17 schema:isAccessibleForFree true
18 schema:isPartOf N9dd07c55fb1a4458a62f46192874397c
19 Nd63eaf2dd2274caaa4fd3b540da6437e
20 sg:journal.1044057
21 schema:keywords ANCOVA
22 CRP
23 HSP70
24 HbA1c
25 MethodsA
26 ObjectiveTo
27 TNFα
28 UAE
29 albumin excretion
30 arm
31 baseline measures
32 biomarkers
33 blood pressure
34 blood pressure values
35 clinical trials
36 combination
37 comparative efficacy
38 comparison
39 copeptin
40 days
41 diabetes
42 diabetic nephropathy
43 diastolic blood pressure values
44 differences
45 dose
46 effect
47 effect of pentoxifylline
48 effect size
49 efficacy
50 excretion
51 first arm
52 generation
53 group
54 high dose
55 high-dose losartan
56 hs-CRP
57 hs-CRP levels
58 intervention
59 levels
60 losartan
61 losartan arm
62 losartan group
63 management
64 markers
65 measures
66 nephropathy
67 number generation
68 open-label clinical trial
69 patients
70 pentoxifylline
71 pressure
72 pressure values
73 random number generation
74 reduction
75 role
76 sample t
77 second arm
78 serum markers
79 significant differences
80 size
81 software
82 superior reduction
83 systolic blood pressure
84 test variance
85 time
86 treatment
87 trial arms
88 trials
89 two times
90 type 2
91 types
92 values
93 variance
94 weeks
95 schema:name Effects of Pentoxifylline on Serum Markers of Diabetic Nephropathy in Type 2 Diabetes
96 schema:pagination 1023-1036
97 schema:productId N09fb51da44c44fd8b62222f5bffaaf6c
98 N1b70115dee244e14a2bac71b4c184fe6
99 Nca1d26cef6f346c682b50441483688f6
100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1146889445
101 https://doi.org/10.1007/s13300-022-01250-y
102 schema:sdDatePublished 2022-08-04T17:11
103 schema:sdLicense https://scigraph.springernature.com/explorer/license/
104 schema:sdPublisher Nf853f984b80f4b6aa9329880a662b9d5
105 schema:url https://doi.org/10.1007/s13300-022-01250-y
106 sgo:license sg:explorer/license/
107 sgo:sdDataset articles
108 rdf:type schema:ScholarlyArticle
109 N09fb51da44c44fd8b62222f5bffaaf6c schema:name doi
110 schema:value 10.1007/s13300-022-01250-y
111 rdf:type schema:PropertyValue
112 N1368c938ed8740bab362d487950468f2 rdf:first sg:person.010117632767.86
113 rdf:rest Ne7f57bdff04a4c02b3f45fb847ade95b
114 N1b70115dee244e14a2bac71b4c184fe6 schema:name dimensions_id
115 schema:value pub.1146889445
116 rdf:type schema:PropertyValue
117 N93be8b3b24fd405baf56d71170091914 rdf:first sg:person.0774664154.25
118 rdf:rest Nbdc1df25bf7546fa8595814ee4b981d1
119 N9dd07c55fb1a4458a62f46192874397c schema:volumeNumber 13
120 rdf:type schema:PublicationVolume
121 Nb30cf3c7370c4e77b43486f93f63f107 rdf:first sg:person.01261073742.61
122 rdf:rest rdf:nil
123 Nbdc1df25bf7546fa8595814ee4b981d1 rdf:first sg:person.013442560033.29
124 rdf:rest Nd5dfeae17ddf43a6b3c15350702f4283
125 Nca1d26cef6f346c682b50441483688f6 schema:name pubmed_id
126 schema:value 35380410
127 rdf:type schema:PropertyValue
128 Nce779a2b0abf490eb7938485cc99e642 rdf:first sg:person.015235114321.53
129 rdf:rest Ne90ed3551fc04472a5fdaffd535b171b
130 Nd5dfeae17ddf43a6b3c15350702f4283 rdf:first sg:person.01244110102.39
131 rdf:rest Nb30cf3c7370c4e77b43486f93f63f107
132 Nd63eaf2dd2274caaa4fd3b540da6437e schema:issueNumber 5
133 rdf:type schema:PublicationIssue
134 Ne7f57bdff04a4c02b3f45fb847ade95b rdf:first sg:person.01222717544.12
135 rdf:rest Nce779a2b0abf490eb7938485cc99e642
136 Ne90ed3551fc04472a5fdaffd535b171b rdf:first sg:person.013767066337.07
137 rdf:rest N93be8b3b24fd405baf56d71170091914
138 Nf853f984b80f4b6aa9329880a662b9d5 schema:name Springer Nature - SN SciGraph project
139 rdf:type schema:Organization
140 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
141 schema:name Medical and Health Sciences
142 rdf:type schema:DefinedTerm
143 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
144 schema:name Clinical Sciences
145 rdf:type schema:DefinedTerm
146 sg:journal.1044057 schema:issn 1869-6953
147 1869-6961
148 schema:name Diabetes Therapy
149 schema:publisher Springer Nature
150 rdf:type schema:Periodical
151 sg:person.010117632767.86 schema:affiliation grid-institutes:grid.411705.6
152 schema:familyName Moosaie
153 schema:givenName Fatemeh
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010117632767.86
155 rdf:type schema:Person
156 sg:person.01222717544.12 schema:affiliation grid-institutes:grid.411705.6
157 schema:familyName Rabizadeh
158 schema:givenName Soghra
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222717544.12
160 rdf:type schema:Person
161 sg:person.01244110102.39 schema:affiliation grid-institutes:grid.411705.6
162 schema:familyName Nakhjavani
163 schema:givenName Manouchehr
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244110102.39
165 rdf:type schema:Person
166 sg:person.01261073742.61 schema:affiliation grid-institutes:grid.411705.6
167 schema:familyName Esteghamati
168 schema:givenName Alireza
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261073742.61
170 rdf:type schema:Person
171 sg:person.013442560033.29 schema:affiliation grid-institutes:grid.411705.6
172 schema:familyName Dehghani Firouzabadi
173 schema:givenName Fatemeh
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013442560033.29
175 rdf:type schema:Person
176 sg:person.013767066337.07 schema:affiliation grid-institutes:grid.411705.6
177 schema:familyName Sheikhy
178 schema:givenName Ali
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013767066337.07
180 rdf:type schema:Person
181 sg:person.015235114321.53 schema:affiliation grid-institutes:grid.411705.6
182 schema:familyName Fallahzadeh
183 schema:givenName Aida
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015235114321.53
185 rdf:type schema:Person
186 sg:person.0774664154.25 schema:affiliation grid-institutes:grid.411705.6
187 schema:familyName Meysamie
188 schema:givenName Alipasha
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774664154.25
190 rdf:type schema:Person
191 sg:pub.10.1007/s11255-015-0968-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025936794
192 https://doi.org/10.1007/s11255-015-0968-2
193 rdf:type schema:CreativeWork
194 sg:pub.10.1007/s12192-010-0204-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1011103613
195 https://doi.org/10.1007/s12192-010-0204-z
196 rdf:type schema:CreativeWork
197 sg:pub.10.1007/s12192-013-0435-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1031112118
198 https://doi.org/10.1007/s12192-013-0435-x
199 rdf:type schema:CreativeWork
200 sg:pub.10.1038/ijo.2008.229 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007469898
201 https://doi.org/10.1038/ijo.2008.229
202 rdf:type schema:CreativeWork
203 sg:pub.10.1038/srep17150 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012845912
204 https://doi.org/10.1038/srep17150
205 rdf:type schema:CreativeWork
206 sg:pub.10.1186/s12933-018-0753-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105978128
207 https://doi.org/10.1186/s12933-018-0753-5
208 rdf:type schema:CreativeWork
209 sg:pub.10.1186/s13098-015-0060-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047012278
210 https://doi.org/10.1186/s13098-015-0060-1
211 rdf:type schema:CreativeWork
212 sg:pub.10.1379/csc-270.1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027491492
213 https://doi.org/10.1379/csc-270.1
214 rdf:type schema:CreativeWork
215 sg:pub.10.2165/00003495-198734010-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002334899
216 https://doi.org/10.2165/00003495-198734010-00003
217 rdf:type schema:CreativeWork
218 grid-institutes:grid.411705.6 schema:alternateName Department of Community Medicine, Tehran University of Medical Sciences, Tehran, Iran
219 Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran
220 schema:name Department of Community Medicine, Tehran University of Medical Sciences, Tehran, Iran
221 Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran
222 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...